Back to top
more

Bausch Health (BHC)

(Delayed Data from NYSE)

$8.60 USD

8.60
2,183,657

-0.06 (-0.69%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $8.61 +0.01 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (160 out of 251)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Wall Street Analysts Believe Bausch (BHC) Could Rally 38.28%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 38.3% in Bausch (BHC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Encompass Health (EHC) Opens Hospital to Boost Presence in Texas

Encompass Health (EHC) opens an inpatient rehabilitation hospital in Prosper to address the diversified needs of the greater Dallas area residents. It marks EHC's 160th nationwide facility.

Has Aveanna Healthcare (AVAH) Outpaced Other Medical Stocks This Year?

Here is how Aveanna Healthcare (AVAH) and Bausch Health (BHC) have performed compared to their sector so far this year.

TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug

Per the deal, Royalty Pharma is set to provide TEVA R&D funding support of up to $125 million to develop olanzapine LAI for treating schizophrenia.

UnitedHealth (UNH) Unit Makes Insulin More Affordable to Avail

UnitedHealth Group's (UNH) sub-unit, Optum Rx, resorts to product shift within its formulary and makes the vital medication of insulin cost-effective, thereby boosting patients' access to it.

Bausch (BHC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Bausch (BHC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

TEVA Q3 Earnings In Line, Sales Beat, Revenue View Raised

TEVA reports decent third-quarter results. The company raises its revenue guidance for 2023 for the second time this year while keeping the EPS range intact.

Bausch Health (BHC) Q3 Earnings & Sales Beat, '23 View Updated

Bausch (BHC) surpasses third-quarter earnings and sales estimates as most of the business units post growth.

Bausch (BHC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Bausch Health (BHC) Earnings Expected to Grow: Should You Buy?

Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Bausch (BHC): Can Its 8.0% Jump Turn into More Strength?

Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?

Here is how Aurinia Pharmaceuticals (AUPH) and Bausch Health (BHC) have performed compared to their sector so far this year.

TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)

TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.

TEVA to Pay $250 Million to Settle Price-Fixing Charges

TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.

New Strong Buy Stocks for August 18th

APP, MELI, MBWM, SHG and BHC have been added to the Zacks Rank #1 (Strong Buy) List on August 18, 2023.

Best Value Stocks to Buy for August 15th

BHC, FBIZ and KB made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 15, 2023.

3 Top-Ranked Value Stocks to Buy as Recession Worries Loom

Invest in companies like BHC, LSEA and TNK, which carry a low price-to-earnings ratio compared to the S&P 500 amid fresh recession worries.

Best Momentum Stock to Buy for August 8th

ACLS, BHC and JHX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2023.

Best Value Stocks to Buy for August 8th

BHC, GPI and UPBD made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 8, 2023.

New Strong Buy Stocks for August 8th

ISNPY, SWDBY, MKL, GPI and BHC have been added to the Zacks Rank #1 (Strong Buy) List on August 8, 2023.

Bausch Health's (BHC) Q2 Earnings & Sales Beat, '23 View Raised

Bausch's (BHC) second-quarter earnings and sales surpass estimates. The company increases its revenue guidance for 2023.

Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bausch Health (BHC) Beats Q2 Earnings and Revenue Estimates

Bausch (BHC) delivered earnings and revenue surprises of 8% and 6.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Secures $600M Financing Facility, Stock Up

Bausch (BHC) enters into a $600 million non-recourse financing facility with KKR to boost liquidity.

Bausch (BHC) Down on Tentative Approval to Xifaxan ANDA

Bausch (BHC) declines after the FDA grants tentative approval to Norwichs ANDA for a generic version of Xifaxan.